Biocon has announced the launch of its first manufacturing facility in the United States, located in Cranbury, New Jersey. The US Food and Drug Administration-approved plant is operated by its wholly owned subsidiary, Biocon Generics, and has the capacity to produce 2 billion oral solid dosage tablets annually.
The company had acquired the plant from Eywa Pharma in 2023 and has invested over $30 million to upgrade it into a state-of-the-art facility. “This investment helps Biocon diversify its manufacturing base, strengthen its supply chain, and accelerate the expansion of its global footprint,” the company stated.
The new site marks a significant step in Biocon’s US operations, aimed at providing faster access to essential therapies and improving supply reliability. While some products are already being manufactured at the facility, more are expected to follow soon.
“Biocon’s first US FDA-approved formulations facility in New Jersey marks a new chapter in our journey of global expansion. More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are,” said Kiran Mazumdar-Shaw, Chairperson of Biocon Group.
The plant was inaugurated on Wednesday in the presence of Phil Murphy, Governor of New Jersey, and several industry leaders. “This strategic investment brings us closer to patients, healthcare providers, and partners in this important market. The proximity allows us to deliver our vertically integrated, high-quality medicines more efficiently to patients across the US and other markets, ensuring supply chain resilience and enabling us to advance our mission of expanding access to affordable therapies worldwide,” said Siddharth Mittal, Chief Executive Officer and Managing Director of Biocon.